drugset

drugset / Trial / NCT00061672

Study Evaluating the Safety and Effectiveness of ABT-510 in Subjects With Refractory Lymphoma

NCT00061672 ↗

Phase 2 Completed 67 enrolled Abbott

Non-randomizedSingle-groupOpen-labelTreatment

Summary

The primary objective of this study is to assess the safety and effectiveness of ABT-510 in subjects with refractory lymphoma.

Timeline

Start: 2003-04
Primary completion: —
Completion: —

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	ABT-510	Peptide	—	—

Indications